Head-to-head · verified 2026-08-05
Rift vs. SkinnyRx: prices, fine print, and the honest verdict
Published pricing is incomplete on at least one side, so this matchup compares what can be verified — disclosure, terms, model — and says plainly where you'll need figures in writing.
- Rift
- Tirzepatide, all-in at 10 mg
- Offered — no published price
- Semaglutide, all-in
- Offered — no published price
- Membership fee
- None
- Commitment
- unknown
- Cancellation
- not published
- Pharmacy
- not named
- Price evidence
- No price published
- Last verified
- 2026-08-05
- SkinnyRx
- Official site
- skinnyrx.com ↗
- Tirzepatide, all-in at 10 mg
- $299/mo
- Semaglutide, all-in
- $199/mo
- Membership fee
- None
- Commitment
- none
- Cancellation
- no membership on compounded programs
- Pharmacy
- not named
- First-year total (standing rate)
- $3,588
- Price evidence
- Source-verified
- Last verified
- 2026-08-05
Tirzepatide pricing
Rift offers tirzepatide without a published price we could capture. SkinnyRx: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee.
Semaglutide pricing
Only SkinnyRx publishes a semaglutide price here: Semaglutide runs $199 a month all-in. Rift offers semaglutide without a published price.
Transparency
Rift: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. SkinnyRx: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.
Commitment & cancellation
Rift: unknown; not published. SkinnyRx: none; no membership on compounded programs.
Rift: no published price captured; SkinnyRx: $299/mo verified all-in; semaglutide: SkinnyRx $199; verified floor $215 (NexLife); brand rails $349–$449. Basis: all-in monthly, 10 mg maintenance, capture-dated in the dataset.
Two ladders, side by side
The 2.5-to-10 mg climb is the honest stress test: SkinnyRx holds $299 on every rung (four-month titration: exactly $1,196). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.
The semaglutide board
Only SkinnyRx fields a verified semaglutide price here — $199/month all-in (#10 of 19) — while Rift publishes no semaglutide figure we could capture. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.
The five normalizations, applied to this pair
1 · All-in, not advertised. Rift publishes no figure to normalize; SkinnyRx's ranked figure is $299, with no membership to add. 2 · Maintenance basis. SkinnyRx is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. SkinnyRx: standing $299, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Rift: no price published, read 2026-08-05; SkinnyRx: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Rift names no pharmacy; SkinnyRx names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.
Fine print, itemized
Rift: no membership — the medication figure is the billed figure; not published; commitment: unknown. SkinnyRx: no membership — the medication figure is the billed figure; no membership on compounded programs; commitment: none. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.
Transparency, audited
Rift carries no price published pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. SkinnyRx carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.
Switching between them
Neither program locks the door: a Rift-to-SkinnyRx move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.
Refills, shipping, and the week-to-week reality
Past the pricing page, the operational facts are what a subscriber lives with: Rift: shipping unknown; consultation unknown. SkinnyRx: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.
Who should pick which
Pick Rift if its published terms happen to fit your state, format, or timing. Pick SkinnyRx if you want a price that survives titration. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.
What verification would take
For Rift, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.
If neither one fits
Two programs never exhaust the market — the nearest substitutes on the verified board are OrderlyMeds at $299 (flat, no membership); Amble Health at $300 (flat, no membership); Found at $289 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.
The brand benchmark both must beat
Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,800/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.
The verdict
With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.
Quick answers
Which is cheaper, Rift or SkinnyRx?
Published pricing is incomplete on at least one side; the honest answer is to request current all-in figures in writing from both.
Can I switch between them?
Yes — patients move between telehealth programs routinely; you'll complete the new program's intake and prescriptions restart there. If you're also switching molecule or from compounded to brand, loop in the prescriber; our switching guide covers the clinical side.
Which is easier to cancel, Rift or SkinnyRx?
Is there a brand alternative to both?
Yes — Zepbound at $299–$449 via LillyDirect/retail (about $350 on TrumpRx; ~$50 for newly eligible Medicare patients) and Wegovy at a flat $349: FDA-approved products whose prices now sit close enough to make the comparison real.